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Abstract
Background: Pulmonary system dysfunction is a hallmark of cystic fibrosis (CF) disease. In addition to impaired
cystic fibrosis transmembrane conductance regulator protein, dysfunctional β2-adrenergic receptors (β2AR)
contribute to low airway function in CF. Recent observations suggest CF may also be associated with impaired
cardiac function that is demonstrated by attenuated cardiac output (Q), stroke volume (SV), and cardiac power (CP)
at both rest and during exercise. However, β2AR regulation of cardiac and peripheral vascular tissue, in-vivo, is
unknown in CF. We have previously demonstrated that the administration of an inhaled β-agonist increases SV
and Q while also decreasing SVR in healthy individuals. Therefore, we aimed to assess cardiac and peripheral
hemodynamic responses to the selective β2AR agonist albuterol in individuals with CF.
Methods: 18 CF and 30 control (CTL) subjects participated (ages 22 ± 2 versus 27 ± 2 and BSA = 1.7 ± 0.1 versus
1.8 ± 0.0 m2, both p < 0.05). We assessed the following at baseline and at 30- and 60-minutes following nebulized
albuterol (2.5mg diluted in 3.0mL of normal saline) inhalation: 12-lead ECG for HR, manual sphygmomanometry
for systolic and diastolic blood pressure (SBP and DBP, respectively), acetylene rebreathe for Q and SV. We calculated
MAP = DBP + 1/3(SBP–DBP); systemic vascular resistance (SVR) = (MAP/Q)•80; CP = Q•MAP; stroke work (SW) = SV•MAP;
reserve (%change baseline to 30- or 60-minutes). Hemodynamics were indexed to BSA (QI, SVI, SWI, CPI, SVRI).
Results: At baseline, CF demonstrated lower SV, SVI, SW, and SWI but higher HR than CTL (p < 0.05); other measures did
not differ. At 30-minutes, CF demonstrated higher HR and SVRI, but lower Q, SV, SVI, CP, CPI, SW, and SWI versus CTL
(p < 0.05). At 60-minutes, CF demonstrated higher HR, SVR, and SVRI, whereas all cardiac hemodynamics were lower
than CTL (p < 0.05). Reserves of CP, SW, and SVR were lower in CF versus CTL at both 30 and 60-minutes (p < 0.05).
Conclusions: Cardiac and peripheral hemodynamic responsiveness to acute β2AR stimulation via albuterol is
attenuated in individuals with CF, suggesting β2AR located in cardiac and peripheral vascular tissue may be
dysfunctional in this population.
Background
A well-recognized phenotype of cystic fibrosis (CF) dis-
ease includes signs and symptoms of chronic sinusitis
and pulmonary airway dysfunction, which are strong
predictors of morbidity and mortality in individuals with
this disease [1–6]. Primary structural and physiological
changes that occur within the pulmonary system, in-
cluding low airway surface fluid, attenuated mucociliary
clearance, and airway obstruction are caused by mecha-
nisms that impair chloride (Cl−) and sodium (Na+) regu-
lation specifically related to malfunctioning or absent
cystic fibrosis transmembrane conductance regulator
(CFTR) protein, and impaired epithelial Na+ channel
(ENaC) inhibition [2, 7–10]. Structural and physiological
abnormalities of the pulmonary system in CF disease
readily transgress to functional impairments as assessed
by airway and gas-transfer tests. Low forced expiratory
volume in one second (FEV1), attenuated capacity of gas
transfer within lungs, and reduced oxygen uptake (VO2)
at rest and during exercise are leading pulmonary system
abnormalities in CF [4, 6, 8, 9, 11, 12]; which, more
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importantly, strongly relate with morbidity and mortality
in this population [1–3, 5, 6, 12].
Important evidence is accumulating that suggests certain
individuals with CF demonstrate impaired β2-adrenergic
receptor (β2AR) function in pulmonary airways [13–19].
Blunted resting pulmonary airway function in addition to
attenuated airway responsiveness following inhalation of
the selective β2AR agonist albuterol may be linked to dys-
function of airway β2AR in CF [13, 14]. In fact, Marson
et al. further suggests that impaired spirometry responses
following inhalation of albuterol indicates disease severity
in CF [14].
In this context and taking into account that β2AR are
found in abundant concentrations in pulmonary as well
as cardiac and systemic vascular tissue [13–20]; observa-
tions relating pulmonary airway dysfunction to impaired
airway β2AR in CF are noteworthy and may have critical
clinical implications in this population [13, 14, 19]. As
such, our group and others have shown that individuals
with CF demonstrate attenuated cardiac output (Q),
large arterial dysfunction, abnormal ventilatory me-
chanics, and attenuated lung gas-transfer [8, 9, 11, 12, 21].
Cumulatively, these observations suggest that there is
global cardiovascular system impairment in individuals
with CF; and, that the hallmark clinical phenotype of this
disease is not isolated to pulmonary system dysfunction.
Accordingly, because we have previously demonstrated
that inhalation of albuterol evokes increases in Q and
stroke volume (SV) that accompany decreases in sys-
temic vascular resistance (SVR) in healthy individuals
[22], the aim of the present study was to assess cardiac
and peripheral vascular function in response to acute in-
halation of the β2AR selective-agonist albuterol in order
to enhance our understanding of whether pathways re-
lated to β2AR in cardiac and peripheral vascular tissue
are impaired, and associated with attenuated cardiac and




Forty-eight adults participated in this cross-sectional
study (CF = 18; healthy individuals = 30 [controls])
(characteristics, Table 1). Cystic fibrosis in individuals
was confirmed by a positive sweat test (≥60.0 millimole/
liter Cl−) and genotyping of the ΔF508 mutation of CFTR.
Individuals with CF who met the following exclusion cri-
teria were not enrolled due to safety concerns: experi-
enced a pulmonary exacerbation within the last two weeks
or pulmonary hemorrhage within six months resulting in
greater than 50 cc of blood in the sputum, were taking
any antibiotics for pulmonary exacerbation, or if they were
taking any experimental drugs related to CF. The Arizona
Respiratory Center and its affiliated CF clinic at the
University of Arizona Medical Center were used to recruit
all individuals with CF. Word of mouth and posted ad-
vertising around the University of Arizona were used to
recruit control participants. The protocol was reviewed
and approved by the University of Arizona Institutional
Review Board. All participants provided written informed
consent prior to study, and all aspects of the study were
performed according to the Declaration of Helsinki.
Protocol overview
Prior to arrival for study participation, individuals were
asked to refrain from caffeine and exercise for 24 h be-
fore arrival for study testing. Upon arrival to the envir-
onmentally controlled physiology laboratory for baseline
Table 1 Participant characteristics
Control Cystic fibrosis P
n 30 18
Age, years 27±2 22±2 0.04
Gender, male/female 18/12 13/5 0.54
Height, cm 172±2 167±2 0.07
Weight, kg 71±2 64±4 0.09
Body mass index, kg/m2 24±1 23±1 0.32
Body surface area, m2 1.8±0.0 1.7±0.1 0.04
Blood urea nitrogen, mg/dL 14.4±0.8 15.1±1.1 0.61
Serum creatinine, mg/dL 1.01±0.03 0.92±0.04 0.18
Serum sodium, mEq/L 139±0 138±1 0.11
Serum chloride, mEq/L 105±0 103±1 0.20
Albuterol dose (body weight standardized)
Mean, μg/kg 36±1.2 41.0±2.0 0.04
Functional capacity and physical activity
Peak oxygen uptake, mL/kg/min 35.1±2.1 23.7±2.2 <0.01
Peak oxygen uptake, % of predicted 97±6 55±5 <0.01
Exercise hours/week (self report) 7±1 9±3 0.23
Pulmonary function test parameters
Forced vital capacity (L) 4.6±0.2 3.7±0.3 0.01
Forced vital capacity (%predicted) 97.3±2.8 83.2±4.7 0.02
FEV1 (L) 3.7±0.1 2.7±0.3 <0.01
FEV1 (%predicted) 94.7±2.6 73.8±6.1 <0.01
FEV1/FVC 0.8±0.0 0.7±0.0 <0.01
FEF25-75 (L/sec) 3.7±0.1 2.2±0.4 <0.01
FEF25-75 (%predicted) 89.6±4.0 54.2±8 <0.01
Medications (n)
Bronchodilators (e.g. ProAir) 0 13
Taking >1 bronchodilator 0 4
Antibiotics (oral or inhaled) 0 14
Inhaled (e.g. Tobramycin) 0 9
Data are mean±SEM or as n. FEV1, forced expiratory volume in one second;
FEF25-75 = forced expiratory flow at 25.0 – 75.0 % of forced vital capacity
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testing, participants were fitted with a 12-lead electro-
cardiogram (Marquette Electronics, Milwaukee, WI) to
monitor heart rate (HR) and rhythm. A single venous
puncture blood draw (2 × 5 mL samples) occurred to as-
sess hemoglobin and renal function. Following blood
sampling standard pulmonary function testing (i.e. flow
volume loop: forced expiratory volume at 25 to 75 % of
FVC (FEF25-75), forced expiratory volume at 25 % of
FVC (FEF25), forced expiratory volume at 50 % of FVC
(FEF50), and forced expiratory volume at 75 % of FVC
(FEF75)) in a seated upright position, using a Medical
Graphics CPFS system spirometer (Medical Graphics, St.
Paul, MN) according to the guidelines of the American
Thoracic Society were performed in triplicate to ensure
all measures fell within 10 % of each attempt [23].
Remaining in the upright position, participants had sys-
tolic (SBP) and diastolic (DBP) pressures assessed using
manual sphygmomanometry. Assessment of Q followed
using the acetylene rebreathe technique as described
previously and in brief below [24]. All cardiovascular
measurements were performed at baseline and at both
30-minutes (30min) and 60-minutes (60min) following
administration of albuterol (described below). For each
measurement time point we calculated the following: mean
arterial blood pressure (MAP) =DBP + 1/3(SBP–DBP);
body mass index =weight/height2; body surface area
(BSA)=
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
height  weight = 3600ð Þp ; SVR=(MAP/Q)•80;
SV=Q/HR; cardiac power (CP)=Q•MAP; stroke work
(SW)=SV•MAP; and reserve (delta=30- or 60-minutes
minus baseline; or, percentage change=baseline to 30min
or 60min) [25–27]. All cardiac hemodynamic measure-
ments and SVR were also indexed separately to BSA: CPI,
SWI, SVI, QI, and SVRI.
Although not a primary aim of this study, to assess
overall functional capacity (i.e. peak VO2), participants
performed a seated upright peak cycle ergometry test to
volitional fatigue (symptom limited) as described and re-
ported previously by our group [8]. This assessment oc-
curred on a separate study visit that was separated by at
least 48 h but no greater than 1 week prior to participa-
tion in the present study. Predicted peak VO2 values
were calculated according to Hansen et al. [28].
Administration of albuterol
Following baseline testing and a brief rest period, partici-
pants were instructed to complete inhalation of the se-
lective β2AR agonist albuterol (albuterol sulfate 2.5 mg
diluted in 3.0 mL of normal saline) using a mouthpiece
connected to a nebulizer (Power Neb2 nebulizer, Port
Washington, NY) in a seated upright position. Using the
mouthpiece—nebulizer system, individuals were instruc-
ted to breathe in calmly, deeply, and evenly for about 5-15
minutes until mist stopped forming in the nebulizer
chamber. At 30min and 60min following albuterol admin-
istration, blood pressures were assessed in addition to Q
in a similar manner to baseline.
Measurement of cardiac output
In a seated upright position, participants breathed into a
non-rebreathing technician controlled pneumatic swit-
ching Y-valve that was connected to a pneumotach-
ometer and mass spectrometer. The inspiratory port of
the switching valve allowed for rapid operator controlled
switching between breathing room air or from a 5.0 L
anesthesia rebreathe bag containing 1575 mL of test gas
(0.65 % acetylene [C2H2], 9.0 % helium [He], 55.0 %
nitrogen, and 35.0 % O2 as previously described [24].
Each rebreathe measurement period consisted of 8-10
consecutive breaths set at a cadence of 32 breaths/min
using a metronome. During each rebreathe period, indi-
viduals were instructed to nearly empty the bag with
each inspiration while the mass spectrometer was used
to collect serial measurement of gas concentrations
starting at end-expiration of the first breath during the
rebreathe period which enabled rapid calculations of Q
[24]. Acetylene disappears in the blood according to the
rate at which pulmonary blood flow occurs, and there-
fore Q is calculated from the slope of the exponential
disappearance of acetylene with respect to the insoluble
gas He [24, 29, 30].
Statistical analysis
All parametric data are presented as means ± standard
error mean (SEM). The data were distributed normally.
Homogeneity of variance of data was confirmed using
Levene’s test. For comparisons of participant characteris-
tics, Wilcoxon rank-sum tests were performed for vari-
ables except gender, which was compared using a χ2 test.
Two-way ANOVA with repeated measures was used to
test for the effect of participant and repeated mea-
surement of hemodynamics. In the event of a significant
F-test statistic, post-hoc testing with a Bonferroni cor-
rection was used. In addition, post-hoc Cohen’s d effect
sizes (small=0.2; medium= 0.5; and large=0.8) were cal-
culated to estimate the magnitude of effects for dif-
ferences between groups at each level of time for cardiac
hemodynamic and SVR indices [31, 32]. The alpha level
was set at 0.05 to determine two-tailed statistical signifi-
cance. All computations were made using SAS statistical
software v.9.4 (SAS Institute Inc., Cary, NC).
Results
Study population
Baseline participant characteristics are presented in Table 1.
Although controls did not have significantly higher body
weight or body mass index compared to CF, none of the
controls had evidence of nutritional deficiency. Although
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the absolute dose of albuterol was identical for all partici-
pants, because of the low body weight in individuals with
CF, the dose of albuterol standardized for body weight
resulted in a higher dose in CF compared to controls.
Compared to controls, CF demonstrated lower functional
capacity as indicated by a lower VO2peak and percentage
achieved of predicted VO2peak. As expected, spirometry
tests prior to albuterol inhalation indicated pulmonary air-
way function was normal in controls but not in CF.
Heart rate and peripheral vascular hemodynamics
Reported in Table 2 are absolute measurements of HR,
SBP, DBP, MAP, SVR, and SVRI assessed at baseline and
at 30 and 60 min following inhalation of albuterol in
participants. No significant interaction was observed for
any test. Fixed effects from ANOVA models for participant
(CF and controls) and condition (baseline, 30 min, and 60
min) were F(1, 47) = 10.91, p = 0.002, and F(2, 96) = 4.73,
p = 0.011 for SVR, respectively; and, F(1, 47) = 18.13,
p<0.0001, and F(2, 96) = 3.61, p = 0.0308 for SVRI,
respectively.
At baseline, modest tachycardia was present in CF ver-
sus controls; although, all other variables were similar be-
tween groups. Differences in HR between groups at rest
persisted to 30min (p<0.05), which was accompanied by
higher SVRI in CF compared to controls (p<0.05). Dif-
ferences between groups at 30min persisted to 60min,
which included significance for HR, SVR, and SVRI.
Cohen’s d effect sizes between CF and controls for SVR
and SVRI progressively increased from baseline (0.31 and
0.50) to 30min (0.54 and 0.73) to 60min (0.82 and 0.93),
respectively, suggesting that the differences between
groups could be largely attributable to CF disease.
Within group differences comparing baseline to 30 or
60 min following albuterol showed no significant differ-
ences for any metric in CF. In contrast, at baseline, both
SVR and SVRI were significantly higher compared to
60min in controls, suggesting an influence of albuterol
on increasing systemic vascular conductivity and perme-
ability in controls.
Cardiac hemodynamics
Presented in Table 3 are traditional measures of cardiac
hemodynamics including Q, QI, SV, and SVI, in addition
to measures of cardiac pumping capability (i.e. CP, CPI,
SW, and SWI) [25, 27]. No significant interaction effects
were observed. From baseline to 60min, differences be-
tween groups in cardiac hemodynamics progressively in-
creased, which were mainly due lack of increases in CF.
This suggested that there was an influence of albuterol
inhalation on increasing cardiac hemodynamics and ar-
terial pressure generation in controls but not in CF.
Increased effect sizes from baseline to 60 min following
albuterol inhalation suggested that the differences be-
tween groups for cardiac hemodynamics were likely due
to null responses in CF (Table 3).
Cardiac and peripheral hemodynamic reserve
Presented in Figs. 1, 2 and 3 are CP, CPI, SW, SWI, SVR,
and SVRI reserves measured as differences between
baseline and 30min or 60min following albuterol inhal-
ation in participants.
We report in Fig. 1 (a–d), absolute differences (Δ) be-
tween baseline and 30min or 60min for CP, CPI, SW,
and SWI following albuterol inhalation in CF and con-
trols. In Panel A, Cohen’s d effect sizes between CF and
controls for ΔCP were 0.62 at 30min and 0.77 at 60 min.
In Panel B, Cohen’s d effect sizes between groups for
ΔCPI were 0.66 at 30 min and 0.73 at 60 min. In Panel
C, Cohen’s d effect sizes between groups for ΔSW were
0.67 at 30 min and 0.99 at 60 min. In Panel D, Cohen’s d
effect sizes between groups for ΔSWI were 0.71 at 30
min and 1.01 at 60 min. The effect sizes at 30 min and
to a greater extent at 60 min suggested a strong influ-
ence of CF disease on cardiac hemodynamic reserve re-
sponses to albuterol.
In Fig. 2 (a and b), we show percentage (%) change
from baseline to 30min or 60min for CPI and SWI fol-
lowing inhalation of albuterol in CF and controls.
Table 2 Heart rate and peripheral vascular function
Minutes after albuterol
Baseline 30 min 60 min
Variable
Heart rate (beats/min)
CF 88±4 92±4 92±4
CTL 74±2* 77±2* 76±2*
Systolic blood pressure (mm Hg)
CF 104±2 104±2 103±2
CTL 109±2 107±2 108±2
Diastolic blood pressure (mm Hg)
CF 70±3 67±3 68±3
CTL 72±2 68±1 70±1
Mean arterial pressure (mm Hg)
CF 82±2 76±3 80±2
CTL 84±1 81±1 83±1
SVR (dynes·sec/cm5)
CF 1415±94 1276±96 1337±106
CTL 1301±60† 1095±50 1044±50*
SVRI (dynes·sec/cm
5/m2)
CF 837±61 756±63 794±72
CTL 720±39† 603±30* 577±31*
Data presented as means±SEM. CF cystic fibrosis (n=18), CTL healthy
individuals (n=30), SVR systemic vascular resistance, SVRI, systemic vascular
resistance index; *CF vs. CTL, p<0.05; †baseline vs. 60 min, p<0.05
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Consistent with Fig. 1 (a–d) at 30 min in CF, there was a
profound decrease in %SWI at 30min following albuterol
inhalation in CF. In Panel A, Cohen’s d effect sizes be-
tween CF and controls for %CPI were 0.60 at 30 min
and 0.75 at 60 min. In Panel B, Cohen’s d effect sizes be-
tween CF and controls for %SWI were 0.81 at 30 min
and 1.05 at 60 min. Observations in Fig. 2 (a and b) were
consistent with Fig. 1 (a–d) for absolute differences.
Lastly, Fig. 3 (a and b) shows Δ and % change, respect-
ively, for SVRI from baseline to 30 min or 60 min follow-
ing inhalation of albuterol in participants. In Panel A,
Cohen’s d effect sizes between CF and controls for ΔSVRI
were 0.24 at 30 min and 0.74 at 60 min. In Panel B,
Cohen’s d effect sizes between CF and controls for %SVRI
were 0.27 at 30 min and 0.84 at 60 min. These effect sizes
suggested that there was a strong influence of CF disease
Table 3 Cardiac hemodynamics
Minutes after albuterol
Baseline 30 min 60 min
Variable
Cardiac output (L/min)
F(1, 47)=15.72, p=0.0002; F(2, 96)=4.02, p=0.021
CF 4.9±0.3 (0.38) 5.2±0.3 (0.72) 5.2±0.4 (0.88)
CTL 5.5±0.3† 6.2±0.3* 6.7±0.3*
Cardiac index (L/min/m2)
F(1, 47)=6.11, p=0.0172; F(2, 96)=4.29, p=0.0165
CF 2.9±0.2 (0.06) 3.0±0.2 (0.45) 3.1±0.2 (0.64)
CTL 3.0±0.1† 3.4±0.1 3.7±0.2*
Stroke volume (mL)
F(1, 47)=27.79, p<0.0001; F(2, 96)=2.01, p=0.139
CF 59±5 (0.76) 62±6 (0.82) 60±6 (1.15)
CTL 74±3*† 82±5* 89±5*
Stroke volume index (mL/m2)
F(1, 47)=20.74, p<0.0001; F(2, 96)=2.28, p=0.108
CF 34±3 (0.66) 36±3 (0.68) 35±3 (1.01)
CTL 41±2*† 45±3* 49±3*
Cardiac power (L/min∙mm Hg)
F(1, 47)=20.90, p<0.0001; F(2, 96)=2.49, p=0.088
CF 401±27 (0.46) 386±23 (0.90) 415±29 (0.96)
CTL 466±27† 505±26* 554±27*
Cardiac power index (L/min∙mm Hg/m2)
F(1, 47)=13.14, p=0.0007; F(2, 96)=3.12, p=0.048
CF 234±15 (0.26) 225±11 (0.76) 242±16 (0.81)
CTL 252±13† 275±13* 301±13*
Stroke work (mL∙mm Hg)
F(1, 47)=35.98, p<0.001; F(2, 96)=1.55, p=0.218
CF 4786±384 (0.80) 4464±331 (1.09) 4763±463 (1.21)
CTL 6269±345*† 6610±401* 7334±405*
Stroke work index (mL∙mm Hg/m2)
F(1, 47)=32.59, p<0.001; F(2, 96)=1.92, p=0.1530
CF 2707±184 (0.77) 2567±147 (1.02) 2741±234 (1.09)
CTL 3423±176*† 3630±217* 4024±217*
Data presented as means±SEM. CF cystic fibrosis (n=18); CTL healthy individuals (n=30); Contained within parentheses are effect sizes (Cohen’s d) between CF and
CTL; F-statistics from two-way ANOVA with repeated measures for fixed effects shown for participant (CF and CTL) and condition (baseline, 30 min, 60 min),
respectively; *CF vs. CTL, p<0.05; †baseline vs. 60 min, p<0.05
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on the attenuated SVRI response to albuterol at 60 min
and to a lesser extent at 30 min.
Overall, cardiac and SVR reserves were consistent with
absolute measures presented in Tables 2 and 3, sug-
gesting individuals with CF did not demonstrate normal
cardiac and peripheral hemodynamic reserve responses
to the β2AR selective-agonist albuterol.
Discussion
In this study we present novel observations which sug-
gest that individuals with CF demonstrate attenuated
cardiac and peripheral hemodynamic responses to acute
inhalation of the β2AR selective-agonist albuterol. The
present findings support the hypothesis that mechanistic
pathways closely associated with impaired β2AR function
BA
C D
Fig. 1 Data presented as means ± standard error mean. Cystic fibrosis (CF, n=18); healthy controls (CTL, n=30). Cardiac hemodynamic reserves
calculated as the delta (Δ) at 30 or 60 minutes following albuterol inhalation minus baseline. Panels A and B, show reserves of cardiac power or
cardiac power indexed for body surface areas (BSA) in individuals with CF versus CTL. Panels C and D, show reserves of stroke work (SW) or SW
indexed for BSA in individuals with CF versus CTL. *CF versus CTL, p<0.05; †Within group, p<0.05
Fig. 2 Data presented as means ± standard error mean. Cystic fibrosis (CF, n=18); healthy controls (CTL, 10.1186/s12931-015-0270-y n=30). Cardiac
hemodynamic reserves calculated as a percentage change (%) from baseline to 30 or 60 minutes following albuterol inhalation. Panel A, shows
cardiac power reserve indexed to body surface area (BSA) in individuals with CF versus CTL. Panel B, shows stroke work reserve indexed to BSA in
individuals with CF versus CTL. *CF versus CTL, p<0.05; †Within group, p<0.05
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are likely determinants of cardiac and peripheral vas-
cular dysfunction in CF. In this context, we show, 1) al-
though absolute measures of baseline SV and SW are
significantly lower in CF compared to controls, this at-
tenuation in CF persists even with β2AR stimulation via
albuterol. Whereas, in response to albuterol inhalation,
healthy individuals in the present study and previously
[22] demonstrate significant increases in cardiac he-
modynamics; 2) similar to null cardiac hemodynamic re-
sponses to albuterol inhalation, vascular conductivity
and permeability indicated by absolute measures of SVR
are not responsive to albuterol inhalation in CF. In con-
trast, and consistent with previous observations from
our group [22], reductions in SVR at 60 min following
albuterol in healthy individuals suggest that improve-
ments in peripheral vascular conductivity are related to
β2AR stimulation; 3) differences in cardiac and periph-
eral hemodynamics from baseline to 30 or 60 min fol-
lowing albuterol inhalation suggest that individuals with
CF are nearly entirely absent of cardiac and peripheral
hemodynamic reserves, whereas healthy individuals are
not; and finally, 4) although we did not assess exercise
responses in the present study, these data are consistent
with previous observations which clearly demonstrate
that individuals with CF have attenuated cardiac he-
modynamic responses to exercise and, hence, impaired
cardiac reserve [9, 11]. Therefore, because arterial pres-
sure is highly blood-flow mediated in the presence of in-
tact cardiac hemodynamic function [33, 34], a decrease
in vasodilatory reserve accompanied by an attenuated
rise in cardiac hemodynamics could likely explain negli-
gible SVR decreases following albuterol inhalation in CF.
Recent observations in animal models of CF suggest
that abnormal cardiac structure, rhythmicity, and con-
tractility in CF are associated with absent and/or
dysfunctional CFTR [35, 36]. This is important since
mutations in genes coding for CFTR are the cause of CF,
and deranged or absent expression of CFTR is respon-
sible for mechanisms leading to pulmonary dysfunction
in individuals with this disease [2, 7–10].
The role of CFTR in contributing to the maintenance
of electrochemical ion balance extends beyond the pul-
monary system, whereby functional CFTR mediate pro-
tein kinase A-stimulated Cl− currents in myocardial
tissue, which is a relationship suggested to act to protect
against ischemia or rhythm disturbances [37]. However,
despite a well-known presence of β2AR in myocardial
tissue, which are critically important in compensating
for loss of β1AR and contractility, particularly in the
condition of heart failure [20]; to date, it remains unclear
what role impaired β2AR have in mediating cardiac dys-
function in CF. In this context, this is a noteworthy gap
in knowledge as it is suggested that β2AR may have an
important role in regulating CFTR-mediated Cl− se-
cretion and intracellular Ca2+ in the pulmonary system
[38–41]. Thus, despite a more clear understanding of re-
lationships between CFTR and β2AR pathways in pul-
monary function [40, 42], any link CFTR shares with
β2AR responsiveness in cardiac and peripheral vascular
tissue is currently unknown in CF disease. This is an im-
portant question to answer since individually, or in an
integrated capacity, mechanisms of CFTR, β2AR, and
global cardiovascular system function appear related and
markedly impaired in individuals with CF.
Although yet to be fully elucidated, it has been ob-
served that alpha-1 adrenergic receptor (α1AR) sen-
sitivity may be augmented in CF [43], which could lead
to abnormal decreases in vasodilatory reserve. A height-
ened α1AR effector response of coronary and peripheral
arteries to selective adrenergic sensitization could
exacerbate a state of attenuated β2AR function. Hyperex-
citability of α1AR in parallel with blunted systemic β2AR
activity could lead to attenuated vasodilatory reserve
and, hence, a negligible drop in SVR following albuterol
Fig. 3 Data presented as means ± standard error mean. Cystic fibrosis (CF, n=18); healthy controls (CTL, n=30). Panel A, systemic vascular resistance
(SVR) reserve indexed to body surface area was calculated as delta (Δ) at 30 or 60 minutes following albuterol inhalation minus baseline in individuals
with CF versus CTL. Panel B, SVR index calculated as the percentage change (%) from baseline to 30 or 60 minutes following albuterol inhalation in
individuals with CF versus CTL. *CF versus CTL, p<0.05
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inhalation. Therefore, because both α1- and β2-AR are
highly involved in the regulation of Ca2+ flux that is essen-
tial for normal excitability and excitation-contraction
coupling in cardiac myocytes and relaxation in smooth
muscle [44–47], paradoxical differences in α1- and β2-AR
receptor responsiveness may have critical consequences
on cardiac and peripheral vascular function in CF. Dual,
but imbalanced, sensitization of α1- and β2-AR via albute-
rol in cardiac and vascular tissue, where α1AR sensitivity
is heightened and β2AR responsiveness is blunted could
result in a critical reduction in intracellular Ca2+, thereby
leading to an impaired rise in myocardial contractility
that is accompanied by decreased relaxation of smooth
muscle [46].
As such, because of shared pathways which contribute
to the influence of β2AR on CFTR-mediated Cl
− regu-
lation [38–42]; impaired β2AR, CFTR, Cl
−, and Ca2+
mechanisms likely play a critical role in the cardiac and
peripheral vascular hemodynamic health of individuals
with CF. The present observations demonstrate clinical
relevance as they suggest that β2AR selective-agonist
therapy intended to alleviate signs and symptoms of pul-
monary dysfunction in CF may be contraindicated in
certain individuals. β2AR selective-agonists such as albu-
terol could augment effector responses of α1AR stimula-
tion in the presence of diminished β2AR function. This
could potentially contribute to an exacerbation of Ca2+
and Cl− channel dysregulation leading to impaired
excitation-contraction coupling in cardiac myocytes and
uncoupling in smooth muscle and, hence, cardiac
dysfunction concurrent with attenuations in vascular
permeability and conductivity in individuals with CF.
Moreover, as β1AR outnumber β2AR in a ~3:1 ratio in
cardiac tissue [20], while also demonstrating sensitivity
(lesser) to albuterol [48], acute increases in HR may
indeed be a potential consequence of β2AR selective-
agonist therapy, thereby causing unanticipated tachycar-
dia. Although, consistent with pharmacokinetic studies
of albuterol in CF and in healthy individuals [49], tachy-
cardia that individuals with CF demonstrated in the
present study was not likely due to the influences of
albuterol, since elevated HR at rest persisted, but did not
increase further at 30- and 60-minutes following albuterol.
These data present novel evidence for the potential
role of cardiac and smooth muscle tissue β2AR pathways
as targets for novel therapies in the management of signs
and symptoms associated with global cardiovascular dys-
function in individuals with CF.
Limitations
The present study was a cross-sectional design and
pharmacokinetic testing was not conducted to assess
systemic absorption of albuterol. However, both albute-
rol and method of delivery utilized in the present study
have been previously demonstrated to elicit pulmonary
function responses in CF and in healthy individuals and,
therefore, we do not believe another confounding factor
was causal for hemodynamic responses measured at 30
and 60 min following albuterol inhalation [13, 14, 22].
Moreover, detailed pharmacokinetic studies of inhaled
albuterol in CF and healthy individuals show that despite
similar inhaled body weight standardized dose con-
centrations of albuterol, albuterol absorption in the
systemic circulation is markedly higher in CF compared
to controls (area under the curve=1051.6±256.2 vs.
277.5±91.5 ng×sec/mL, respectively) [49]. Also, in com-
parison to systemic absorption of albuterol, it is esti-
mated that only ~10% of inhaled albuterol is absorbed in
pulmonary tissue [49], suggesting that in the presence of
intact β2AR, there is a stronger likelihood of response at
the systemic level compared to the pulmonary system.
Lastly, the present study did not specifically test β1AR or
α1AR function, nor intracellular Ca
2+ or Cl− as a result
of albuterol inhalation in participants. Therefore, our
hypotheses regarding the relationships between these
factors warrants further study of the integrated roles of
CFTR, α1AR, β1,2AR, Ca
2+, Cl−, and cardiac and vascular
function in individuals with CF.
Conclusions
The major findings of this study suggests that individuals
with CF do not demonstrate cardiac and peripheral vascu-
lar hemodynamic responsiveness to the short-acting β2AR
selective-agonist albuterol that mirror normal responses of
healthy individuals. We suggest that null cardiac and per-
ipheral vascular hemodynamic responses to acute albuterol
inhalation in individuals with CF are likely due to deranged
β2AR function, closely accompanied by impaired CFTR
and related pathways leading to augmented Cl− and Ca2+
dysregulation in cardiac and vascular smooth muscle.
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